FDAsafety guidance72% confidence
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Merck Sharp & Dohme LLC.
Regulatory Analysis
Learn more about actions to accelerate and modernize clinical research across the full continuum of drug development —from the Investigational New Drug (IND) phase to late-stage pivotal trials.
Supporting Context
- Therapeutic area
- Hematology · CLL/SLL
- Sub-indication
- General
Related signal: Phase II Trial of Nemtabrutinib with CAR T-cell Therapy in Relapsed/Refractory CLL/SLL